AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), VDCCs blockers(Voltage-gated calcium channel blockers)

Therapeutic Areas

Cardiovascular DiseasesEndocrinology and Metabolic Disease

Active Indication

HypertensionDyslipidemias

Inactive Indication

Essential HypertensionHyperlipidemias

Originator Organization

Boryung Corp.

Active Organization

Boryung Corp.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

KR (23 May 2020),

Dyslipidemias

Regulation-

Structure

Molecular FormulaC26H31ClN2O8S

InChIKeyZPBWCRDSRKPIDG-UHFFFAOYSA-N

CAS Registry111470-99-6

View All Structures (3)

Clinical Trials associated with Amlodipine Besylate/Fimasartan Potassium Trihydrate/Rosuvastatin Calcium

NCT03156842 / CompletedPhase 3

A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia Who Fail to Respond Adequately to Fimasartan Monotherapy

The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/amlodipine/rosuvastatin treatment group to the fimasartan/amlodipine treatment group and the fimasartan/rosuvastatin treatment group respectively at Week 8 in patients with essential hypertension and dyslipidemia who fail to respond to the fimasartan monotherapy.

Start Date29 May 2017

Sponsor / Collaborator

Boryung Corp.

NCT02995720 / CompletedPhase 1

An Open-label, Randomized, Single-dose, 2X3X3 Partial Replicate, Crossover Study to Compare the Pharmacokinetics and Safety Between a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin and Co-administration of a Fixed Dose Combination of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects

An open-label, randomized, single-dose, 2X3X3 partial replicate, crossover study to compare the pharmacokinetics and safety between a fixed dose combination of Fimasartan/Amlodipine/Rosuvastatin and Co-administration of a fixed dose combination of Fimasartan/Amlodipine and Rosuvastatin in healthy male subjects.

Start Date26 Aug 2016

Sponsor / Collaborator

Boryung Corp.

NCT02569814 / CompletedPhase 1

A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin

A Open-label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics and Safety between a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin versus Co-administration of a Fixed Dose Combination of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects.

Start Date01 Sep 2015

Sponsor / Collaborator

Boryung Corp.

100 Clinical Results associated with Amlodipine Besylate/Fimasartan Potassium Trihydrate/Rosuvastatin Calcium

100 Translational Medicine associated with Amlodipine Besylate/Fimasartan Potassium Trihydrate/Rosuvastatin Calcium

100 Patents (Medical) associated with Amlodipine Besylate/Fimasartan Potassium Trihydrate/Rosuvastatin Calcium

100 Deals associated with Amlodipine Besylate/Fimasartan Potassium Trihydrate/Rosuvastatin Calcium

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypertension	KR	Boryung Corp.	29 May 2020
Dyslipidemias	KR	Boryung Corp.	23 May 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Essential Hypertension	Phase 2	KR	Boryung Corp.	29 May 2017
Hyperlipidemias	Preclinical	-	Boryung Corp.	26 Aug 2016
Hypertension	Preclinical	-	Boryung Corp.	26 Aug 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis